# m6A demethylase–driven reprogramming of leukemia-associated macrophages predicts improved outcomes in acute myeloid leukemia

**Authors:** Zhiyu Shi, Yuan Xia, Mingyue Zhang, Ying Peng, Yun An, Qingjun Zhu, Tao Sun

PMC · DOI: 10.3389/fimmu.2026.1739959 · 2026-02-03

## TL;DR

This study shows that m6A demethylase activity in macrophages affects their function and can predict better outcomes in acute myeloid leukemia patients.

## Contribution

The paper reveals a novel link between m6A demethylase activity in macrophages and improved prognosis in AML, suggesting new therapeutic strategies.

## Key findings

- Macrophages with high eraser activity show M1-like pro-inflammatory traits and are linked to better AML patient outcomes.
- Reader-high macrophages adopt an immunosuppressive M2-like phenotype, while m6A-deficient cells show functional exhaustion.
- RT-qPCR validation confirms higher eraser expression in AML patients with favorable prognosis.

## Abstract

N6-methyladenosine (m6A) is a dynamic mRNA modification influencing transcript fate and cellular identity, especially in cancer. While oncogenic roles of m6A regulators in AML cells are known, their impact on the leukemic immune microenvironment is unclear.

In this study, we constructed a single-cell atlas of macrophages in AML by integrating publicly available scRNA-seq datasets from 129 patient cohorts. Data were batch-corrected using Seurat and Harmony. Macrophage subpopulations were identified, and the expression and activity of 29 m6A regulators were analyzed. Pseudotime analysis (Monocle3), cell–cell communication (CellChat), and pathway enrichment (Metascape) analyses were performed to explore m6A-related functional programs. Survival analysis was conducted using Kaplan–Meier curves. RT-qPCR was used to verify the correlation between m6A regulatory molecules and prognosis.

Our findings indicated that m6A regulators are associated with macrophage fate. Writer-high macrophages showed enhanced proliferation and differentiation, maintaining monocyte-like features. Eraser-high macrophages remodeled macrophage function toward an M1-like, pro-inflammatory and antigen-presenting state. Reader-high macrophages drove macrophages toward an immunosuppressive, M2-like phenotype, while m6A-deficient cells exhibit features of functional exhaustion. Survival analysis based on bulk RNA-seq data further revealed that m6A-regulated macrophage profiles were associated with distinct prognostic stratification in AML patients. RT-qPCR analysis of macrophages isolated from clinical AML samples further validated these findings, showing that patients with favorable prognosis exhibited significantly higher expression levels of erasers compared to those with poor prognosis.

These results highlight m6A system’s role in macrophage reprogramming and suggest that targeting m6A regulators in macrophages may serve as a potential basis for prognostic stratification and a promising therapeutic strategy in AML.

## Linked entities

- **Diseases:** acute myeloid leukemia (MONDO:0015667)

## Full-text entities

- **Genes:** YTHDC2 (YTH N6-methyladenosine RNA binding protein C2) [NCBI Gene 64848] {aka CAHL, hYTHDC2}, VCAN (versican) [NCBI Gene 1462] {aka CSPG2, ERVR, GHAP, PG-M, WGN, WGN1}, FMR1 (fragile X messenger ribonucleoprotein 1) [NCBI Gene 2332] {aka FMRP, FRAXA, POF, POF1}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, CBLL1 (Cbl proto-oncogene like 1) [NCBI Gene 79872] {aka HAKAI, RNF188}, FTH1 (ferritin heavy chain 1) [NCBI Gene 2495] {aka FHC, FTH, FTHL6, HFE5, NBIA9, PIG15}, S100A8 (S100 calcium binding protein A8) [NCBI Gene 6279] {aka 60B8AG, CAGA, CFAG, CGLA, CP-10, L1Ag}, HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1) [NCBI Gene 3181] {aka HNRNPA2, HNRNPB1, HNRPA2, HNRPA2B1, HNRPB1, IBMPFD2}, MKI67 (marker of proliferation Ki-67) [NCBI Gene 4288] {aka KIA, MIB-, MIB-1, PPP1R105}, CD99 (CD99 molecule (Xg blood group)) [NCBI Gene 4267] {aka HBA71, MIC2, MIC2X, MIC2Y, MSK5X}, ALOX5 (arachidonate 5-lipoxygenase) [NCBI Gene 240] {aka 5-LO, 5-LOX, 5LPG, LOG5}, RBM33 (RNA binding motif protein 33) [NCBI Gene 155435] {aka PRR8}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, UPF3A (UPF3A regulator of nonsense mediated mRNA decay) [NCBI Gene 65110] {aka HUPF3A, RENT3A, UPF3}, CTNNA1 (catenin alpha 1) [NCBI Gene 1495] {aka CAP102, MDBS2, MDPT2}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, ELAVL1 (ELAV like RNA binding protein 1) [NCBI Gene 1994] {aka ELAV1, HUR, Hua, MelG}, IRAK3 (interleukin 1 receptor associated kinase 3) [NCBI Gene 11213] {aka ASRT5, IRAKM}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, YTHDF1 (YTH N6-methyladenosine RNA binding protein F1) [NCBI Gene 54915] {aka C20orf21, DF1}, YTHDF3 (YTH N6-methyladenosine RNA binding protein F3) [NCBI Gene 253943] {aka DF3}, TRIM28 (tripartite motif containing 28) [NCBI Gene 10155] {aka KAP1, PPP1R157, RNF96, TF1B, TIF1B, TIF1beta}, HNRNPC (heterogeneous nuclear ribonucleoprotein C) [NCBI Gene 3183] {aka HNRNP, HNRPC, MRD74, SNRPC}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, FANCB (FA complementation group B) [NCBI Gene 2187] {aka FA2, FAAP90, FAAP95, FAB, FACB}, YTHDF2 (YTH N6-methyladenosine RNA binding protein F2) [NCBI Gene 51441] {aka CAHL, DF2, HGRG8, NY-REN-2}, FTL (ferritin light chain) [NCBI Gene 2512] {aka FTL1, LFTD, NBIA3}, S100A9 (S100 calcium binding protein A9) [NCBI Gene 6280] {aka 60B8AG, CAGB, CFAG, CGLB, L1AG, LIAG}, LRPPRC (leucine rich pentatricopeptide repeat containing) [NCBI Gene 10128] {aka CLONE-23970, GP130, LRP130, LSFC, MC4DN5}, YTHDC1 (YTH N6-methyladenosine RNA binding protein C1) [NCBI Gene 91746] {aka YT521, YT521-B}, HNRNPH1 (heterogeneous nuclear ribonucleoprotein H1) [NCBI Gene 3187] {aka HNRPH, HNRPH1, NEDCDS, hnRNPH}, RSRP1 (arginine and serine rich protein 1) [NCBI Gene 57035] {aka C1orf63, NPD014}, PRPF3 (pre-mRNA processing factor 3) [NCBI Gene 9129] {aka HPRP3, HPRP3P, PRP3, Prp3p, RP18, SNRNP90}, RBMX (RNA binding motif protein X-linked) [NCBI Gene 27316] {aka HNRNPG, HNRPG, MRXS11, MRXSG, MRXSH, RBMXRT}, METTL5 (methyltransferase 5, N6-adenosine) [NCBI Gene 29081] {aka HSPC133, MRT72}, RBM15 (RNA binding motif protein 15) [NCBI Gene 64783] {aka OTT, OTT1}, METTL16 (methyltransferase 16, RNA N6-adenosine) [NCBI Gene 79066] {aka METT10D}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, METTL14 (methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit) [NCBI Gene 57721] {aka hMETTL14}, PCIF1 (phosphorylated CTD interacting factor 1) [NCBI Gene 63935] {aka C20orf67, CAPAM, MT-A70, PPP1R121, hCAPAM, hPCIF1}, RBM15B (RNA binding motif protein 15B) [NCBI Gene 29890] {aka HUMAGCGB, HsOTT3, OTT3}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, RPL17 (ribosomal protein L17) [NCBI Gene 6139] {aka DBA22, L17, PD-1, RPL23, uL22}, ZCCHC4 (zinc finger CCHC-type containing 4) [NCBI Gene 29063] {aka HSPC052, ZGRF4}, METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56339] {aka IME4, M6A, MT-A70, Spo8, hMETTL3}, SOAT1 (sterol O-acyltransferase 1) [NCBI Gene 6646] {aka ACACT, ACAT, ACAT-1, ACAT1, SOAT, STAT}, IL34 (interleukin 34) [NCBI Gene 146433] {aka C16orf77, IL-34}, ZC3H13 (zinc finger CCCH-type containing 13) [NCBI Gene 23091] {aka KIAA0853, Xio}, ACTG1 (actin gamma 1) [NCBI Gene 71] {aka ACT, ACTG, DFNA20, DFNA26, HEL-176}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2) [NCBI Gene 10644] {aka IMP-2, IMP2, VICKZ2}, RPS6 (ribosomal protein S6) [NCBI Gene 6194] {aka S6, eS6}, TYROBP (transmembrane immune signaling adaptor TYROBP) [NCBI Gene 7305] {aka DAP12, KARAP, PLOSL, PLOSL1}, CD47 (CD47 molecule) [NCBI Gene 961] {aka IAP, MER6, OA3}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, FTO (FTO alpha-ketoglutarate dependent dioxygenase) [NCBI Gene 79068] {aka ALKBH9, BMIQ14, GDFD, IFEX9}, SLC25A36 (solute carrier family 25 member 36) [NCBI Gene 55186] {aka HHF8, PNC2}, IGF2BP3 (insulin like growth factor 2 mRNA binding protein 3) [NCBI Gene 10643] {aka CT98, IMP-3, IMP3, KOC, KOC1, VICKZ3}, FCER1G (Fc epsilon receptor Ig) [NCBI Gene 2207] {aka FCRG}
- **Diseases:** osteosarcoma (MESH:D012516), inflammation (MESH:D007249), PAAD (MESH:D010190), Tumor (MESH:D009369), AML (MESH:D015470), hematologic malignancies (MESH:D019337), hypoxia (MESH:D000860), metastasis (MESH:D009362), death (MESH:D003643), LAMs (MESH:D007938), bladder, gastric, and colorectal cancers (MESH:D015179), atherosclerosis (MESH:D050197), breast cancer (MESH:D001943), TNBC (MESH:D064726)
- **Chemicals:** N6-methyladenosine (MESH:C010223), iron (MESH:D007501), TRIzol (MESH:C411644), m6A-deficient (-), m6A (MESH:C005955), PBS (MESH:D007854)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12909554/full.md

---
Source: https://tomesphere.com/paper/PMC12909554